Source link : https://www.newshealth.biz/health-news/year-in-review-multiple-myeloma/
Advances in multiple myeloma treatment this year were marked by the resurrection of a drug that had been previously pulled off the market, new FDA approvals, and research suggesting that an isatuximab (Sarclisa)-based quadruplet could be the new standard of care for transplant-ineligible patients with newly diagnosed disease. A Second Chance for Belantamab Mafodotin One […]
Author : News Health
Publish date : 2024-12-02 16:21:08
Copyright for syndicated content belongs to the linked Source.